With a dedicated emphasis on personalized medicine, our efforts revolve around forging groundbreaking diagnostic solutions based on qPCR and Next Generation Sequencing techniques, coupled with the innovation of nucleic acid therapies, that redefine diagnostics and treatment approaches, ushering in a new era of precision care.

We are dedicated to finding solutions that enhance the healthcare of cancer patients. Our approach involves conducting precise and sensitive analyses of genetic alterations linked to cancer, to improve the accuracy of diagnosis, treatment, and prognosis, tailoring medical interventions to the individual patient's unique genetic profile.

We develop innovative and user-centric solutions designed to detect biomarkers with exceptional accuracy, both within hospital settings and beyond, ensuring seamless applicability in various environments.

We contribute to the evolution of cutting-edge therapeutic nucleic acids by developing novel RNA sequences (short and long RNA). We are also pushing beyond the boundaries of the current state-of-the-art in drug delivery with lipid nanoparticles (LNPs), focusing on ionizable lipids and refined formulations. These accomplishments will not only improve delivery efficiency, but also enable precise targeting for enhanced therapeutic outcomes.